GEO series

USP18 impacts on platinum-resistance in ovarian cancer cells by modulating DNA repair

GSE326132 Homo sapiens (human) RNA-seq (gene expression) 51 samples Submitted 2026/05/29 Platform GPL34284

At a glance

RNA-seq (gene expression) · human · 51 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Topic: Ovarian cancerThis series is part of our curated briefing on it.
Samples: 51 samples: 17 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: USP18 Impacts Cisplatin Resistance in Ovarian Cancer Cells by Modulating DNA RepairInternational journal of biological sciences · 2026

Summary (written by the submitters)

Aims: Deubiquitinases (DUBs) are proteases with emerging roles in cancer progression and therapy resistance, yet their contribution to drug resistance in ovarian cancer remains underexplored. Ovarian cancer patients often fail to benefit from platinum-based therapy, highlighting the need to identify novel factors involved in drug resistance.

Read the full summary ↓

To this end we performed a CRISPR/Cas9 screen targeting DUB family to identify genes essential for platinum- resistant ovarian carcinoma cell survival. Methods: A CRISPR/CAS9 DUB knockout screen was performed on IGROV-1 parental and platinum-resistant ovarian carcinoma cells. Preclinical pharmacology approaches were also applied. Results: We identified USP18 as a survival factor in platinum-resistant ovarian cancer cells. USP18 expression was elevated at the mRNA and protein levels across five platinum-resistant cell lines. Knockdown and CRISPR/CAS9 editing of USP18 sensitized cells to cisplatin, coinciding with impaired repair of cisplatin-induced DNA damage. RNA-seq of USP18 RNA interfered and edited cells revealed the modulation of pathways including DNA repair. A peptide-based USP18 inhibitor suppressed growth of resistant cells, supporting its role in sustaining the growth of platinum-resistant cells. Conclusion: We identified USP18 as a novel mediator of platinum resistance in ovarian cancer, through modulating DNA repair. Targeting USP18 may offer a therapeutic strategy to improve outcomes in platinum-resistant ovarian cancer.

Published in

USP18 Impacts Cisplatin Resistance in Ovarian Cancer Cells by Modulating DNA Repair

Corno C, Costantino M, Pettinari P et al. · International journal of biological sciences 2026 · PMID 42328450 · doi:10.7150/ijbs.130399

This dataset

Open GSE326132 in finder → Find more human RNA-seq datasets → Ovarian cancer landscape →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE326132_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1444006 and SRA study SRP687125. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 42328450) ↗

Study design

17 conditions, mostly in triplicate

KO, IGROV-1/Pt1, CTR, ×3 KO, IGROV-1/Pt1, WT C7, ×3 KO, IGROV-1/Pt1, WT E10, ×3 KO, IGROV-1/Pt1, KO C2, ×3 KO, IGROV-1/Pt1, KO C14, ×3 KD, IGROV-1/Pt1, untransfected, ×3 KD, IGROV-1/Pt1, negative, ×3 KD, IGROV-1/Pt1, siRNAb, ×3 +9 more

Supports a between-group comparison across 51 samples.

How we read this: 17 replicated groups read from 51 sample titles; they account for 51 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM9623740 KO, IGROV-1/Pt1, CTR, rep1 KO, IGROV-1/Pt1, CTR,
GSM9623741 KO, IGROV-1/Pt1, CTR, rep2 KO, IGROV-1/Pt1, CTR,
GSM9623742 KO, IGROV-1/Pt1, CTR, rep3 KO, IGROV-1/Pt1, CTR,
GSM9623743 KO, IGROV-1/Pt1, WT C7, rep1 KO, IGROV-1/Pt1, WT C7,
GSM9623744 KO, IGROV-1/Pt1, WT C7, rep2 KO, IGROV-1/Pt1, WT C7,
GSM9623745 KO, IGROV-1/Pt1, WT C7, rep3 KO, IGROV-1/Pt1, WT C7,
GSM9623746 KO, IGROV-1/Pt1, WT E10, rep1 KO, IGROV-1/Pt1, WT E10,
GSM9623747 KO, IGROV-1/Pt1, WT E10, rep2 KO, IGROV-1/Pt1, WT E10,
GSM9623748 KO, IGROV-1/Pt1, WT E10, rep3 KO, IGROV-1/Pt1, WT E10,
GSM9623749 KO, IGROV-1/Pt1, KO C2, rep1 KO, IGROV-1/Pt1, KO C2,
GSM9623750 KO, IGROV-1/Pt1, KO C2, rep2 KO, IGROV-1/Pt1, KO C2,
GSM9623751 KO, IGROV-1/Pt1, KO C2, rep3 KO, IGROV-1/Pt1, KO C2,
GSM9623752 KO, IGROV-1/Pt1, KO C14, rep1 KO, IGROV-1/Pt1, KO C14,
GSM9623753 KO, IGROV-1/Pt1, KO C14, rep2 KO, IGROV-1/Pt1, KO C14,
GSM9623754 KO, IGROV-1/Pt1, KO C14, rep3 KO, IGROV-1/Pt1, KO C14,
GSM9623755 KD, IGROV-1/Pt1, untransfected, rep1 KD, IGROV-1/Pt1, untran…
GSM9623756 KD, IGROV-1/Pt1, untransfected, rep2 KD, IGROV-1/Pt1, untran…
GSM9623757 KD, IGROV-1/Pt1, untransfected, rep3 KD, IGROV-1/Pt1, untran…
GSM9623758 KD, IGROV-1/Pt1, negative, rep1 KD, IGROV-1/Pt1, negati…
GSM9623759 KD, IGROV-1/Pt1, negative, rep2 KD, IGROV-1/Pt1, negati…
GSM9623760 KD, IGROV-1/Pt1, negative, rep3 KD, IGROV-1/Pt1, negati…
GSM9623761 KD, IGROV-1/Pt1, siRNAb, rep1 KD, IGROV-1/Pt1, siRNAb,
GSM9623762 KD, IGROV-1/Pt1, siRNAb, rep2 KD, IGROV-1/Pt1, siRNAb,
GSM9623763 KD, IGROV-1/Pt1, siRNAb, rep3 KD, IGROV-1/Pt1, siRNAb,
GSM9623764 KD, IGROV-1/Pt1, siRNAc, rep1 KD, IGROV-1/Pt1, siRNAc,
GSM9623765 KD, IGROV-1/Pt1, siRNAc, rep2 KD, IGROV-1/Pt1, siRNAc,
GSM9623766 KD, IGROV-1/Pt1, siRNAc, rep3 KD, IGROV-1/Pt1, siRNAc,
GSM9623767 KD, PEO4, untransfected, rep1 KD, PEO4, untransfected,
GSM9623768 KD, PEO4, untransfected, rep2 KD, PEO4, untransfected,
GSM9623769 KD, PEO4, untransfected, rep3 KD, PEO4, untransfected,
GSM9623770 KD, PEO4, negative, rep1 KD, PEO4, negative,
GSM9623771 KD, PEO4, negative, rep2 KD, PEO4, negative,
GSM9623772 KD, PEO4, negative, rep3 KD, PEO4, negative,
GSM9623773 KD, PEO4, siRNAb, rep1 KD, PEO4, siRNAb,
GSM9623774 KD, PEO4, siRNAb, rep2 KD, PEO4, siRNAb,
GSM9623775 KD, PEO4, siRNAb, rep3 KD, PEO4, siRNAb,
GSM9623776 KD, PEO4, siRNAc, rep1 KD, PEO4, siRNAc,
GSM9623777 KD, PEO4, siRNAc, rep2 KD, PEO4, siRNAc,
GSM9623778 KD, PEO4, siRNAc, rep3 KD, PEO4, siRNAc,
GSM9623779 KD, A2780CP, untransfected, rep1 KD, A2780CP, untransfec…

+ 11 more — browse all 51 samples with per-sample file links →

More Ovarian cancer datasets

GSE268514 Integrative genomic analysis of Korean high-grade serous ovarian cancer 161 samples same disease briefing · shares ovarian
GSE311212 Transcriptomic profiling in human ovarian cancer cell line OVCAR-3 following CDK2 inhibitor treatment 6 samples same disease briefing · shares ovarian
GSE128098 TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target 4 samples same disease briefing · shares ovarian
GSE154600 Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma 5 samples same disease briefing · shares ovarian
GSE57477 Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes 72 samples same disease briefing · shares ovarian
GSE314300 Rb CUT&RUN profiling in ovarian cancer cell lines following CDK2 inhibitor treatment 10 samples same disease briefing · shares ovarian
GSE135242 Hi-C identifies structural variation associated with resistance in paired patient-derived ovarian cancer models 8 samples same disease briefing · shares ovarian
GSE28330 Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents 107 samples same disease briefing · shares repair

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.